Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 168

1.

A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease.

Bartus RT, Emerich D, Snodgrass-Belt P, Fu K, Salzberg-Brenhouse H, Lafreniere D, Novak L, Lo ES, Cooper T, Basile AS.

J Pharmacol Exp Ther. 2004 Aug;310(2):828-35. Epub 2004 Mar 23.

PMID:
15039453
[PubMed - indexed for MEDLINE]
Free Article
2.

Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease.

Bordia T, Campos C, Huang L, Quik M.

J Pharmacol Exp Ther. 2008 Oct;327(1):239-47. doi: 10.1124/jpet.108.140897. Epub 2008 Jul 23.

PMID:
18650244
[PubMed - indexed for MEDLINE]
Free Article
3.

Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.

Agnati LF, Leo G, Vergoni AV, Martínez E, Hockemeyer J, Lluis C, Franco R, Fuxe K, Ferré S.

Brain Res Bull. 2004 Aug 30;64(2):155-64.

PMID:
15342103
[PubMed - indexed for MEDLINE]
4.

The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease.

Djaldetti R, Rosmarin V, Ziv I, Melamed E.

Clin Neuropharmacol. 2001 Mar-Apr;24(2):95-8.

PMID:
11307044
[PubMed - indexed for MEDLINE]
5.

Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.

St-Hilaire M, Landry E, Lévesque D, Rouillard C.

Neurobiol Dis. 2005 Nov;20(2):450-60.

PMID:
15896973
[PubMed - indexed for MEDLINE]
6.

L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease.

Cooper DR, Marrel C, Testa B, van de Waterbeemd H, Quinn N, Jenner P, Marsden CD.

Clin Neuropharmacol. 1984;7(1):89-98.

PMID:
6704979
[PubMed - indexed for MEDLINE]
7.

Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum.

Lopez A, Muñoz A, Guerra MJ, Labandeira-Garcia JL.

Neuroscience. 2001;103(3):639-51.

PMID:
11274784
[PubMed - indexed for MEDLINE]
8.

Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.

Carlsson T, Winkler C, Burger C, Muzyczka N, Mandel RJ, Cenci A, Björklund A, Kirik D.

Brain. 2005 Mar;128(Pt 3):559-69. Epub 2005 Jan 19.

PMID:
15659429
[PubMed - indexed for MEDLINE]
Free Article
9.

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.

Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.

PMID:
18952677
[PubMed - indexed for MEDLINE]
Free Article
10.

Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.

Menzaghi F, Whelan KT, Risbrough VB, Rao TS, Lloyd GK.

J Pharmacol Exp Ther. 1997 Jan;280(1):393-401.

PMID:
8996220
[PubMed - indexed for MEDLINE]
Free Article
11.

A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.

Tomiyama M, Kimura T, Maeda T, Kannari K, Matsunaga M, Baba M.

Neurosci Res. 2005 Jun;52(2):185-94. Epub 2005 Apr 13.

PMID:
15893579
[PubMed - indexed for MEDLINE]
12.

Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.

Lindén IB, Nissinen E, Etemadzadeh E, Kaakkola S, Männistö P, Pohto P.

J Pharmacol Exp Ther. 1988 Oct;247(1):289-93.

PMID:
3171977
[PubMed - indexed for MEDLINE]
13.

Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems.

Kim TK, Kang W, Chun IK, Oh SY, Lee YH, Gwak HS.

Eur J Pharm Sci. 2009 Dec 8;38(5):525-32. doi: 10.1016/j.ejps.2009.09.019. Epub 2009 Oct 3.

PMID:
19804823
[PubMed - indexed for MEDLINE]
14.

Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.

Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA.

J Neurochem. 2006 Mar;96(6):1718-27.

PMID:
16539687
[PubMed - indexed for MEDLINE]
15.

Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.

Yamada H, Aimi Y, Nagatsu I, Taki K, Kudo M, Arai R.

Neurosci Res. 2007 Sep;59(1):1-7. Epub 2007 May 21.

PMID:
17586078
[PubMed - indexed for MEDLINE]
16.

Peculiarities of L: -DOPA treatment of Parkinson's disease.

Kostrzewa RM, Nowak P, Kostrzewa JP, Kostrzewa RA, Brus R.

Amino Acids. 2005 Mar;28(2):157-64. Epub 2005 Mar 9. Review.

PMID:
15750845
[PubMed - indexed for MEDLINE]
17.

Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease.

Zhang X, Andren PE, Chergui K, Svenningsson P.

Neuropharmacology. 2008 Jun;54(7):1143-52. doi: 10.1016/j.neuropharm.2008.03.005. Epub 2008 Mar 18.

PMID:
18423776
[PubMed - indexed for MEDLINE]
18.

Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.

Kääriäinen TM, García-Horsman JA, Piltonen M, Huotari M, Männistö PT.

Basic Clin Pharmacol Toxicol. 2008 Mar;102(3):300-7. Epub 2007 Oct 31.

PMID:
17973898
[PubMed - indexed for MEDLINE]
19.

Chronic L-dopa administration decreases striatal accumulation of dopamine from exogenous L-dopa in rats with intact nigrostriatal projections.

Melamed E, Globus M, Friedlender E, Rosenthal J.

Neurology. 1983 Jul;33(7):950-3.

PMID:
6683384
[PubMed - indexed for MEDLINE]
20.

Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer.

Kirik D, Georgievska B, Burger C, Winkler C, Muzyczka N, Mandel RJ, Bjorklund A.

Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4708-13. Epub 2002 Mar 26.

PMID:
11917105
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk